Adenosine A1 antagonists and the cardiorenal syndrome

Current Heart Failure Reports

Volumn 5, Issue 2, 2008, Pages 105-109

  Gottlieb, Stephen S ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 HYDROXYETHYL) 1 [3 (2 PHENYLPYRAZOLO[1,5 A]PYRIDIN 3 YL)ACRYLOYL]PIPERIDINE; 3 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)BICYCLO[2.2.2]OCTAN 1 YL]PROPIONIC ACID; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE RECEPTOR AFFECTING AGENT; BENZODIAZEPINE; DIURETIC AGENT; FUROSEMIDE; HYPERTENSIVE FACTOR; INOTROPIC AGENT; NAXIFYLLINE; PLACEBO; ROLOFYLLINE; SILDENAFIL; SLV 320; UNCLASSIFIED DRUG; VASODILATOR AGENT; 1,3 DIPROPYL 8 (2 (5,6 EPOXY)NORBORNYL)XANTHINE; 1,3-DIPROPYL-8-(2-(5,6-EPOXY)NORBORNYL)XANTHINE; 1,3-DIPROPYL-8-(3-NORADAMANTYL)XANTHINE; ADENOSINE A1 RECEPTOR; XANTHINE DERIVATIVE;

BODY WEIGHT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CREATININE CLEARANCE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SPECIFICITY; GLOMERULUS FILTRATION RATE; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LOW DRUG DOSE; NONHUMAN; OPTIMAL DRUG DOSE; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN FUNCTION; REPERFUSION INJURY; REVIEW; SEIZURE; SIDE EFFECT; URINE VOLUME; ANIMAL; DISEASE MODEL; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HEART FAILURE; HOSPITALIZATION; KIDNEY DISEASE; KIDNEY FUNCTION TEST; MALE; MOUSE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SYNDROME; TREATMENT OUTCOME;

ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FUROSEMIDE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MALE; MICE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ADENOSINE A1; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SYNDROME; TREATMENT OUTCOME; XANTHINES;

EID: 58149118273     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-008-0017-x     Document Type: Review

References (26)

1. Balakrishnan VS, Coles GA, Williams JD: Effects of intravenous adenosine on renal function in healthy human subjects. Am J Physiol 1996, 271(2 Pt 2):F374-F381.
2. Kim SM, Mizel D, Huang YG, et al.: Adenosine as a mediator of macula densa-dependent inhibition of renin secretion. Am J Physiol Renal Physiol 2006, 290:F1016-F1023.
3. Vallon V, Muhlbauer B, Osswald H: Adenosine and kidney function. Physiol Rev 2006; 86:901-940.
4. Gellai M, Schreiner GF, Ruffolo RR Jr, et al.: CVT-124, a novel adenosine A1 receptor antagonist with unique diuretic activity. J Pharmacol Exp Ther 1998, 286:1191-1196.
5. Lucas DG Jr, Hendrick JW, Sample JA, et al.: Cardiorenal effects of adenosine subtype 1 (A1) receptor inhibition in an experimental model of heart failure. J Am Coll Surg 2002, 194:603-609.
6. Balakrishnan VS, Coles GA, Williams JD: A potential role for endogenous adenosine in control of human glomerular and tubular function. Am J Physiol 1993, 265(4 Pt 2):F504-F510.
7. Gottlieb SS, Skettino SL, Wolff A, et al.: The effects of BG9719 (CVT-124), an A1 adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in congestive heart failure patients. J Am Coll Cardiol 2000, 35:56-59.
8. Gottlieb SS, Brater DC, Thomas I, et al.: BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 2002, 105:1348-1353.
9. Givertz MM, Massie BM, Fields TK, et al.: The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol 2007, 50:1551-1560.
10. Dittrich HC, Gupta DK, Hack TC, et al.: The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. J Card Fail 2007, 13:609-617.
11. Cleland JG, Coletta AP, Abdellah AT, et al.: Clinical trials update from Heart Rhythm 2007 and Heart Failure 2007: CARISMA, PREPARE, DAVID II, SAVE-PACE, PROTECT and AREA-IN-CHF. Eur J Heart Fail 2007, 9:850-853.
12. Greenberg B, Thomas I, Banish D, et al.: Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo-controlled, dose-escalation study. J Am Coll Cardiol 2007, 50:600-606.
13. Funaya H, Kitakaze M, Node K, et al.: Plasma adenosine levels increase in patients with chronic heart failure. Circulation 1997, 95:1363-1365.
14. Funakoshi H, Zacharia LC, Tang Z, et al.: A1 adenosine receptor upregulation accompanies decreasing myocardial adenosine levels in mice with left ventricular dysfunction. Circulation 2007, 115:2307-2315.
15. Funakoshi H, Chan TO, Good JC, et al.: Regulated over-expression of the A1-adenosine receptor in mice results in adverse but reversible changes in cardiac morphology and function. Circulation 2006, 114:2240-2250.
16. Kalk P, Eggert B, Relle K, et al.: The adenosine A1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephrectomy without affecting blood pressure. Br J Pharmacol 2007, 151:1025-1032.
17. Lankford AR, Yang JN, Rose-Meyer R, et al.: Effect of modulating cardiac A1 adenosine receptor expression on protection with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2006, 290:H1469-H1473.
18. Zucchi R, Cerniway RJ, Ronca-Testoni S, et al.: Effect of cardiac A(1) adenosine receptor overexpression on sarcoplasmic reticulum function. Cardiovasc Res 2002, 53:326-333.
19. Salloum FN, Das A, Thomas CS, et al.: Adenosine A1 receptor mediates delayed cardioprotective effect of sildenafil in mouse. J Mol Cell Cardiol 2007, 43:545-551.
20. Auchampach JA, Jin X, Moore J, et al.: Comparison of three different A1 adenosine receptor antagonists on infarct size and multiple cycle ischemic preconditioning in anesthetized dogs. J Pharmacol Exp Ther 2004, 308:846-856.
21. Baraldi PG, Romagnoli R, Preti D, et al.: Ligands for A2B adenosine receptor subtype. Curr Med Chem 2006, 13:3467-3482.
22. Jacobson KA, Gao ZG: Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006, 5:247-264.
23. Schwarzschild MA, Agnati L, Fuxe K, et al.: Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci 2006, 29:647-654.
24. Bar-Yehuda S, Silverman MH, Kerns WD, et al.: The anti-inflammatory effect of A3 adenosine receptor agonists: A novel targeted therapy for rheumatoid arthritis. Expert Opin Investig Drugs 2007, 16:1601-1613.
25. Gan TJ, Habib AS: Adenosine as a non-opioid analgesic in the perioperative setting. Anesth Analg 2007, 105:487-494.
26. Hosseinmardi N, Mirnajafi-Zadeh J, Fathollahi Y, Shahabi P: The role of adenosine A1 and A2A receptors of entorhinal cortex on piriform cortex kindled seizures in rats. Pharmacol Res 2007, 56:110-117.